Literatur
-
1
Bertz J, Giersiepen K, Haberland J. et al .
Krebs in Deutschland. 5., überarb. aktual. Ausgab.
Robert Koch Institut.
2006;
32-35
-
2
Vasen H F, Wijnen J.
Clinical implications of genetic testing of hereditary nonpolyposis colorectal cancer.
Cytogenet Cell Genet.
1999;
86
136-139
-
3
Lynch H T, de la Chapelle A.
Genetic susceptibility to non-polyposis colorectal cancer.
J Med Genet.
1999;
36
801-818
-
4
Aarnio M, Mecklin J P, Aaltonen L A. et al .
Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome.
Int J Cancer.
1995;
64
430-433
-
5
Engel C, Forberg J, Holinski-Feder E. et al .
Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer.
Int J Cancer.
2006;
118
115-122
-
6
Vasen H F, Watson P, Mecklin J P. et al .
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.
Gastroenterology.
1999;
116
1453-1456
-
7
Umar A, Boland C R, Terdiman J P. et al .
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.
J Natl Cancer Inst.
2004;
96
261-268
-
8
Mangold E, Pagenstecher C, Friedl W. et al .
Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining.
J Pathol.
2005;
207
385-395
-
9
Goecke T, Schulmann K, Engel C. et al .
Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium.
J Clin Oncol.
2006;
24
4285-4292
Dr. med. Nicolaus Friedrichs
Institut für Pathologie
Universität Bonn
Sigmund-Freud-Straße 25
53127 Bonn
Email: nicolaus.friedrichs@ukb.uni-bonn.de
